Publicaties
Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger Instituut voor Tropische Geneeskunde
Setting: Niger National Tuberculosis Programme.
Objective: To describe the outcomes and adverse events (AEs) in a cohort of adults, children and adolescents with multidrug-resistant tuberculosis (MDR-TB) who were treated with the 'short-course regimen'.
Design: The regimen comprised an intensive phase of 4-6 months with kanamycin, medium-high dose of isoniazid and prothionamide, and high doses of gatifloxacin, clofazimine, ...
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB Instituut voor Tropische Geneeskunde Universiteit Antwerpen
OBJECTIVES: Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was to determine molecular markers and breakpoints predicting second-line treatment outcomes in M. tuberculosis patients treated with fourth-generation fluoroquinolones.
METHODS: We analysed ...
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB Instituut voor Tropische Geneeskunde
Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB Instituut voor Tropische Geneeskunde
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda Instituut voor Tropische Geneeskunde
Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.
We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time ...
Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: a retrospective cohort stud Instituut voor Tropische Geneeskunde
SETTING: Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regimen was used to treat MDR-TB.
OBJECTIVES: In a post-Ebola context, with a weakened health system, we describe the MDR-TB treatment uptake, patients ...
Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India KU Leuven
Procurement and supply management system for MDR-TB in Nigeria Instituut voor Tropische Geneeskunde
BACKGROUND: The World Health Organisation (WHO) introduced the twelve early warning indicators for monitoring and evaluating drug Procurement and Supply management (PSM) systems, intended to prevent drug stock-outs and overstocking. Nigeria--one of the high Multi Drug Resistant Tuberculosis (MDR-TB) burden countries, scaled-up treatment in 2012 with the concurrent implementation of a PSM system.
METHOD: We evaluated how well this ...
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline Instituut voor Tropische Geneeskunde
OBJECTIVES: Resistance-associated variants (RAVs) in Rv0678, a regulator of the MmpS5-MmpL5 efflux pump, have been shown to lead to increased MICs of bedaquiline (2- to 8- fold) and clofazimine (2- to 4-fold). The prevalence of these Rv0678 RAVs in clinical isolates and their impact on treatment outcomes are important factors to take into account in bedaquiline treatment guidelines.
METHODS: Baseline isolates from two bedaquiline ...